Sign In
Last checked at 
3 Jul 2024 17:28
Syncona Limited (the "Company")
Director Declaration
3 July 2024
In accordance with the requirements of Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies held by the following member of the Board:
Dr Kemal Malik was appointed to the board of directors of Cartesian Therapeutics, Inc (NASDAQ: RNAC) on 1 July 2024.
Enquiries
Syncona Ltd
Alasdair Moodie
Tel: +44 (0) 20 3981 7940
Citco Fund Services (Guernsey) Limited
Company Secretary
Tel: +44 (0) 1481 758200
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.
We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Follow the stocks
